Skip to main content
Clinical Trials/NCT04339283
NCT04339283CompletedNot Applicable

Standardized Hibiscus Sabdariffa Linn Tea, Potential Nutraceutical Candidate for the Prevention of Hypertension, Diabetes, and Hypercholesterolemia - a Pilot Study

University of Ibadan1 site in 1 country32 target enrollmentStarted: September 1, 2019Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
32
Locations
1
Primary Endpoint
Change form Baseline Hemoglobin on the 28th day

Study Overview

Brief Summary

Hibiscus sabdariffa tea is commonly used all over the world by healthy individual but the tea is also employed by patients in the management of chronic diseases such as hypertension diabetes, high cholesterol, liver disease etc. Several studies in humans and animal have proved the efficacy of Hibiscus sabdariffa tea in lowering blood pressure, blood glucose level and serum total cholesterol. But no study exists on the effect of daily consumption of this tea on blood pressure, blood glucose, total cholesterol and other biochemical and hematological parameters in healthy humans. Hence this study.

Detailed Description

Several studies have been carried out on the effect of the water beverage of Hibiscus sabdariffa, most focus on hypertensive patients, diabetic patients and obese patient and some studies investigated the hypolipidemic a effect of the water beverage of Hibiscus sabdariffa as well as its effect on haematological parameters but mice were used for these studies. Little or no investigation has been done to assess the safety of daily consumption of this water beverage of hibiscus sabdariffa on humans.

Hence, this study aims at investigating the safety in the daily consumption of Zobo in humans, monitoring lipid profile, blood pressure, blood glucose, body mass index and haematological parameters such as haematocrit, haemoglobin, total white blood cells and also hepatic indices.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 40 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Healthy volunteers only
  • •Not on any medications or herbs
  • •No disease condition
  • •Females not pregnant
  • •Non-smokers

Exclusion Criteria

  • •Below 18yrs or above 40 years
  • •presence of chronic disease
  • •on medications pregnant females

Arms & Interventions

Standardized Hibiscus sabdariffa tea Arm

Experimental

300 mL of freshly prepared standardized Hibiscus sabdariffa tea (containing 102.49 mg/L of total monomeric anthocyanin) is administered daily to the participants for 28 days

Intervention: Standardized Hibiscus sabdariffa tea (Dietary Supplement)

Water Arm

No Intervention

300 mL of distilled water is administered to the participants daily for 28 days.

Outcomes

Primary Outcomes

Change form Baseline Hemoglobin on the 28th day

Time Frame: 28 days

Hemoglobin was analysed in the laboratory and measured in g/dL on the 28th day

Change form Baseline Total Protein on the 14th day

Time Frame: 14 days

Total Protein was analysed in the laboratory and measured in g/dL on the 14th day

Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure on the 14th day

Time Frame: 14 days

Blood pressure was measured in mmHg at baseline and on the 14th day of study with the aid of Omron Digital Blood pressure monitor

Change from Baseline Fasting Blood Glucose level on the 28th day

Time Frame: 28 days

Fating blood glucose level was measured with AccuChek Active glucometer in mg/dL on the 28th day of study

Change from Baseline Total Serum Cholesterol on the 28th day

Time Frame: 28 days

Total Serum Cholesterol was analysed with Randox kit and measured in mg/dL on the 28th day

Change form Baseline Aspartate Aminotransferase on the 14th day

Time Frame: 14 days

Aspartate aminotransferase was analysed with Randox kit and measured in U/L on the 14th day

Change form Baseline Aspartate Aminotransferase on the 28th day

Time Frame: 28 days

Aspartate aminotransferase was analysed with Randox kit and measured in U/L on the 28th day

Change form Baseline White Blood Cell count on the 28th day

Time Frame: 28 days

White Blood Cell counts was analysed in the laboratory and measured in 10\*3/ µL on the 28th day

Change form Baseline Pulse on the 28th day

Time Frame: 28 days

Pulse was measured with the BP monitor in /min on the 28th day

Change from Baseline Fasting Blood Glucose level on the 14th day

Time Frame: 14 days

Fating blood glucose level was measured with AccuChek Active glucometer in mg/dL on the 14th day of study

Change form Baseline Blood Urea Nitrogen on the 28th day

Time Frame: 28 days

Blood Urea Nitrogen was analysed with Randox kit and measured in mg/dL on the 28th day

Change form Baseline Serum Creatinine on the 14th day

Time Frame: 14 days

Serum Creatinine was analysed with Randox kit and measured in mg/dL on the 14th day

Change form Baseline Serum Creatinine on the 28th day

Time Frame: 28 days

Serum Creatinine was analysed with Randox kit and measured in mg/dL on the 28th day

Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure on the 28th day

Time Frame: 28 days

Systolic and Diastolic Blood pressures were measured in mmHg at baseline and on the 28th day of study with the aid of Omron Digital Blood pressure monitor

Change from Baseline Triglyceride on the 28th day

Time Frame: 28 days

Triglyceride was analysed with Randox kit and measured in mg/dL on the 28th day

Change from Baseline High Density Lipoprotein Cholesterol on the 14th day

Time Frame: 14 days

High Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 14th day

Change from Baseline High Density Lipoprotein Cholesterol on the 28th day

Time Frame: 28 days

High Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 28th day

Change form Baseline Alanine Aminotransferase on the 14th day

Time Frame: 14 days

Alanine aminotransferase was analysed with Randox kit and measured in U/L on the 14th day

Change from Baseline Total Serum Cholesterol on the 14th day

Time Frame: 14 days

Total Serum Cholesterol was analysed with Randox kit and measured in mg/dL on the 14th day

Change from Baseline Triglyceride on the 14th day

Time Frame: 14 days

Triglyceride was analysed with Randox kit and measured in mg/dL on the 14th day

Change form Baseline Alanine Aminotransferase on the 28th day

Time Frame: 28 days

Alanine aminotransferase was analysed with Randox kit and measured in U/L on the 28th day

Change form Baseline Blood Urea Nitrogen on the 14th day

Time Frame: 14 days

Blood Urea Nitrogen was analysed with Randox kit and measured in mg/dL on the 14th day

Change form Baseline Albumin on the 28th day

Time Frame: 28 days

Albumin was analysed with Randox kit and measured in g/dL on the 28th day

Change form Baseline Hematocrit on the 14th day

Time Frame: 14 days

Hematocrit was analysed in the laboratory and measured in % on the 14th day

Change from Baseline Low Density Lipoprotein Cholesterol on the 14th day

Time Frame: 14 days

Low Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 14th day

Change from Baseline Low Density Lipoprotein Cholesterol on the 28th day

Time Frame: 28 days

Low Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 28th day

Change form Baseline Albumin on the 14th day

Time Frame: 14 days

Albumin was analysed with Randox kit and measured in g/dL on the 14th day

Change form Baseline Hemoglobin on the 14th day

Time Frame: 14 days

Hemoglobin was analysed in the laboratory and measured in g/dL on the 14th day

Change form Baseline White Blood Cell count on the 14th day

Time Frame: 14 days

White Blood Cell counts was analysed in the laboratory and measured in 10\*3/ µL on the 14th day

Change form Baseline Pulse on the 14th day

Time Frame: 14 days

Pulse was measured with the BP monitor in /min on the 14th day

Change form Baseline Hematocrit on the 28th day

Time Frame: 28 days

Hematocrit was analysed in the laboratory and measured in % on the 28th day

Change form Baseline Total Protein on the 28th day

Time Frame: 28 days

Total Protein was analysed in the laboratory and measured in g/dL on the 28th day

Secondary Outcomes

  • Change from Baseline Body Mass Index on the 28th day(28 day)
  • Change from Baseline Body Mass Index on the 14th day(14 day)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

SEGUN SHOWANDE

Dr.

University of Ibadan

Study Sites (1)

Loading locations...

Similar Trials